From the Journals

Opioids prescribed for diabetic neuropathy pain, against advice


 

Dr. McCoy offers clinical pearls for treating pain in DPN

Clinically, Dr. McCoy said that she individualizes treatment for painful DPN.

“I tend to use duloxetine if the patient also has a mood disorder including depression or anxiety, because it can also help with that. Gabapentin can also be helpful for radiculopathy or for chronic low-back pain. It can even help with degenerative joint disease like arthritis of the knees. So, you maximize benefit if you use one drug to treat multiple things.”

All three recommended medications are generic now, although pregabalin still tends to be more expensive, she noted. Gabapentin can cause drowsiness, which makes it ideal for a patient with insomnia but much less so for a long-haul truck driver. Duloxetine doesn’t cause sleepiness. Pregabalin can, but less so than gabapentin.

“I think that’s why it’s so important to talk to your patient and ask how the neuropathy is affecting them. What other comorbidities do they have? What is their life like? I think you have to figure out what drug works for each individual person.”

Importantly, she advised, if one of the three doesn’t work, stop it and try another. “It doesn’t mean that none of these meds work. All three should be tried to see if they give relief.”

Nonpharmacologic measures such as cognitive behavioral therapy, acupuncture, or physical therapy may help some patients as well.

Supplements such as vitamin B12 – which can also help with metformin-induced B12 deficiency – or alpha-lipoic acid may also be worth a try as long as the patient is made aware of potential risks, she noted.

Dr. McCoy hopes to repeat this study using national data. “I don’t think this is isolated to Mayo ... I think it affects all practices,” she said.

Since the study, “we [Mayo Clinic] have implemented practice changes to limit use of opioids for chronic pain ... so I hope it’s getting better. It’s important to be aware of our patterns in prescribing.”

The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases. Dr. McCoy reported receiving grants from the AARP Quality Measure Innovation program through a collaboration with OptumLabs and the Mayo Clinic’s Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Incidence of autoimmune hepatitis may be rising
MDedge Family Medicine
Gestational diabetes carries CVD risk years later
MDedge Family Medicine
Plant-based or keto diet? Novel study yields surprising results
MDedge Family Medicine
Bariatric surgery gives 10-year cure for some advanced diabetes
MDedge Family Medicine
PURE: High refined-grain intake boosts death, CVD events
MDedge Family Medicine
Oily fish linked to lower risk of diabetes in largest study to date
MDedge Family Medicine
Long-term metformin use linked to fewer ER+ breast cancers
MDedge Family Medicine
Lifestyle coaching for obesity associated with improved cardiometabolic numbers in study
MDedge Family Medicine
Semaglutide for weight loss? A good first STEP, with caveats
MDedge Family Medicine
Super Bowl ad for diabetes device prompts debate
MDedge Family Medicine